Determination of Record Date and Entitlement
Roquefort Therapeutics plc has confirmed the record date of 30 November 2025 for determining entitlement to new unlisted redeemable non-voting shares, which will carry rights to future commercial benefits from the Company's Midkine Investments portfolio, with the ultimate aim of an in-specie distribution. Further details regarding entitlement ratios and the number of shares to be issued will be announced shortly.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares ("Unlisted RNV Shares"), the Company confirms that the record date for determining entitlement to the Unlisted RNV Shares has now passed.
Holders of ordinary shares and convertible loan notes who were on the Company's registers as at close of business on 30 November 2025 (the "Record Date") will be entitled to receive Unlisted RNV Shares.
The Unlisted RNV Shares will carry the right to all future commercial benefits arising from the Company's Midkine Investments portfolio, with the ultimate intention of facilitating an in-specie distribution of the Midkine Investments shares to the holders of Unlisted RNV Shares when the Company's balance sheet permits such a distribution in accordance with the Companies Act 2006.
Full details of the entitlement ratio, the exact number of Unlisted RNV Shares to be issued, the crediting process and the anticipated timetable will be set out in a further announcement to be made in due course.
Regulatory Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.